RLMD: Relmada Therapeutics, Inc. Stock

by  •  • Comments Off on RLMD: Relmada Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 24.88
Enterprise Value ($M) 23.73
Book Value ($M) 22.44
Book Value / Share 0.68
Price / Book 1.11
NCAV ($M) 22.42
NCAV / Share 0.68
Price / NCAV 1.11

Profitability (mra)
Return on Invested Capital (ROIC) -3.37
Return on Assets (ROA) -0.90
Return on Equity (ROE) -1.05

Liquidity (mrq)
Quick Ratio 5.29
Current Ratio 5.29

Balance Sheet (mrq) ($M)
Current Assets 27.66
Assets 27.68
Liabilities 5.24
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -83.89
Net Income -79.98
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -51.76
Cash from Investing 51.56
Cash from Financing -0.04

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-01 13G Squadron Capital Management LLC 6.20
11-14 13G/A Deep Track Capital, LP 2.24 -66.99

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO
2025-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 1
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-30 186,013 558,687 33.29
2025-05-29 292,240 575,851 50.75
2025-05-28 271,620 1,096,049 24.78
2025-05-27 158,532 623,801 25.41

(click for more detail)

Similar Companies
RGEN – Repligen Corporation RGNX – REGENXBIO Inc.
RIGL – Rigel Pharmaceuticals, Inc. RLYB – Rallybio Corporation
ROIV – Roivant Sciences Ltd.


Financial data and stock pages provided by
Fintel.io